Risky regulatory environment limits Israel's pharma market score by BMI

Israel is again ranked sixth out of the 19 Middle East and African (MEA) markets surveyed by Business Monitor International in its fourth-quarter Business Environment Ratings (BER). Israel still scores strongly across the country reward and country risk categories, due to its urbanized nature and developed economy.

However, says BMI, a risky regulatory environment, particularly with regard to intellectual property (IP) provisions, serves to limit Israel's overall score. Globally, Israel is ranked 46th of the 83 markets surveyed by BMI in its ever-expanding pharmaceutical universe, despite its comparably substantial per-capita spending.

Modest growth to $1.86 billion market in 2014